Evidence map›Paper›PMID 29258194›Full record

ArticleMolecules (Basel, Switzerland)2017

Synergy between Ursolic and Oleanolic Acids from Vitellaria paradoxa Leaf Extract and β-Lactams against Methicillin-Resistant Staphylococcus aureus: In Vitro and In Vivo Activity and Underlying Mechanisms.

Lucy Catteau, Nathalie T Reichmann, Joshua Olson, Mariana G Pinho, Victor Nizet, Françoise Van Bambeke, Joëlle Quetin-Leclercq

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Proanthocyanidins inhibit methicillin-resistantCurrent research in food science · 2026
    Article
  3. Review
  4. Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Lucy CatteauPharmacognosy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Brussels, Belgium. lucy.catteau@uclouvain.be.
Nathalie T ReichmannBacterial Cell Biology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal. nreichmann@itqb.unl.pt.
Joshua OlsonDepartment of Pediatrics, University of California, San Diego, La Jolla, CA 92093-0760, USA. jolson@ucsd.edu.
Mariana G PinhoBacterial Cell Biology Laboratory, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal. mgpinho@itqb.unl.pt.
Victor NizetDepartment of Pediatrics, University of California, San Diego, La Jolla, CA 92093-0760, USA. vnizet@ucsd.edu.ORCID 0000-0003-3847-0422
Françoise Van BambekeCellular and Molecular Pharmacology Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Brussels, Belgium. francoise.vanbambeke@uclouvain.be.ORCID 0000-0002-0052-7991
Joëlle Quetin-LeclercqPharmacognosy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Brussels, Belgium. joelle.leclercq@uclouvain.be.
UCLouvain · BEUniversidade Nova de Lisboa · PTUniversity of California San Diego · US

Funding

Systems Biology Approach to Redefine Susceptibility Testing and Treatment of MDR Pathogens in the Context of Host ImmunityU01AI124316 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALSSON, BERNHARD O · 2016 to 2020
$10.2M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseU54HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIGAM, SANJAY K · 2016 to 2018
$2.2M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAPPARELLI, EDMUND VINCENT, NIZET, VICTOR · 2019 to 2020
$1.4M
European Research Council 310987NIAID NIH HHS U01 AI124316NICHD NIH HHS P50 HD090259NICHD NIH HHS U54 HD090259
6 · The paper itself

Abstract

Combining antibiotics with resistance reversing agents is a key strategy to overcome bacterial resistance. Upon screening antimicrobial activities of plants used in traditional medicine, we found that a leaf dichloromethane extract from the shea butter tree (

Indexed as

AnimalsAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsDrug Resistance, BacterialDrug SynergismEricalesFemaleHydrolysisMethicillin-Resistant Staphylococcus aureusMice, Inbred C57BLMicrobial Sensitivity TestsOleanolic AcidPlant ExtractsPlant LeavesAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsOleanolic AcidPlant ExtractsTriterpenesUrsolic AcidMRSAoleanolic acidPBP2skin infectiontriterpenic acidursolic acidVitellaria paradoxaβ-lactamases

Identifiers

PMID29258194
PMCPMC6149719
OpenAlexW2777698789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.